ArticleScientific reports2025
An exploratory study of high-throughput transcriptomic analysis reveals novel mRNA biomarkers for acute myocardial infarction using integrated methods.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LASSO Regression Analysis: Applications in Dyslipidemia and Cardiovascular Disease Research.Journal of lipid and atherosclerosis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Acute myocardial infarction (AMI) is a major contributor to cardiovascular-related mortality, and early diagnosis is crucial for effective treatment and better outcomes. While several biomarkers have been explored for AMI, there remains a need for reliable, non-invasive biomarkers that can accurately differentiate AMI patients from healthy individuals. This study aims to identify potential mRNA biomarkers in peripheral blood that could aid in the diagnosis and monitoring of AMI. We performed transcriptomic analysis of blood samples from 81 individuals, including 16 healthy controls, 58 AMI patients, and 7 post-treated AMI individuals. Through a combination of Sparse Partial Least Squares-Discriminant Analysis (sPLS-DA), random forest (RF), Weighted Gene Co-expression Network Analysis (WGCNA), and LASSO regression, we identified mRNA markers that are significantly correlated with AMI. Specifically, the mRNA expressions of ANKRD52, ART1, NRP2, and PPP1R15A were elevated in AMI patients, whereas BAIAP2L1 and CCNE1 were downregulated. However, while these mRNA biomarkers show potential for distinguishing AMI patients from healthy individuals, further studies are needed to confirm their clinical applicability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.